NEW YORK (GenomeWeb News) – Protein biomarker firm Astute Medical today announced the completion of a $13 million financing.
The financing is an extension of a Series B round completed in May that had raised $26.5 million. The San Diego firm also raised $6.2 million in a Series A round in 2008.
Participants in the $13 million raise included existing investors Domain Associates, Delphi Ventures, De Novo Ventures, and Johnson & Johnson Development Corp.
Astute said it will use proceeds to advance and expand its research, development, and validation of biomarker-based laboratory tests. The company said on its website that it is developing diagnostic tests focused on acute coronary syndromes, abdominal pain, cerebrovascular injury, kidney injury, and sepsis.